Skip to main content

HIPRA delivers the first doses of its vaccine against COVID-19


Spain is the first country to receive doses of BIMERVAX® after its approval on March 30


On Friday, April 28, the biotechnical pharmaceutical company HIPRA delivered the first doses of BIMERVAX®, its vaccine against COVID-19, one month after receiving approval from the European Medicines Agency (EMA) and the European Commission for its commercialization in Europe.

The first country to have the new recombinant protein vaccine has been Spain, which has acquired 3.2 million doses, as announced by the President of the Government, Pedro Sánchez, during his visit to HIPRA in mid-April.


HIPRA is confident that "the first doses of the vaccine can begin to be administered very soon, always following the recommendations of the competent health authorities, and that the vaccine will be included in the next vaccination campaigns".

Spain is one of the 13 member states of the European Union that signed the Joint Procurement Agreement (JPA) under which they have the option to buy up to 250 million doses of the vaccine. The biotechnical also plans to export the vaccine outside the European Union through local distributors and collaborators.